Oppenheimer & Co. Inc. Has $2.73 Million Stock Holdings in CVS Health Corporation (NYSE:CVS)

Oppenheimer & Co. Inc. lowered its position in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 61.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 40,340 shares of the pharmacy operator's stock after selling 63,038 shares during the quarter. Oppenheimer & Co. Inc.'s holdings in CVS Health were worth $2,733,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Norges Bank acquired a new position in shares of CVS Health in the 4th quarter valued at $839,574,000. Capital World Investors increased its stake in shares of CVS Health by 26.6% in the fourth quarter. Capital World Investors now owns 61,039,777 shares of the pharmacy operator's stock worth $2,739,927,000 after acquiring an additional 12,819,148 shares during the last quarter. Davis Selected Advisers increased its stake in shares of CVS Health by 2,998.1% in the fourth quarter. Davis Selected Advisers now owns 11,385,950 shares of the pharmacy operator's stock worth $511,115,000 after acquiring an additional 11,018,438 shares during the last quarter. Dodge & Cox increased its position in CVS Health by 11.2% during the fourth quarter. Dodge & Cox now owns 70,105,899 shares of the pharmacy operator's stock worth $3,147,054,000 after buying an additional 7,075,209 shares during the last quarter. Finally, Pzena Investment Management LLC increased its position in CVS Health by 49.3% during the fourth quarter. Pzena Investment Management LLC now owns 19,610,579 shares of the pharmacy operator's stock worth $880,319,000 after buying an additional 6,475,271 shares during the last quarter. Institutional investors own 80.66% of the company's stock.

CVS Health Price Performance

Shares of CVS Health stock traded up $0.36 during midday trading on Friday, reaching $68.50. The company had a trading volume of 5,937,044 shares, compared to its average volume of 10,889,755. The company has a current ratio of 0.82, a quick ratio of 0.63 and a debt-to-equity ratio of 0.77. The company has a market capitalization of $86.66 billion, a price-to-earnings ratio of 16.35, a price-to-earnings-growth ratio of 0.95 and a beta of 0.56. The stock has a fifty day simple moving average of $64.83 and a 200 day simple moving average of $60.70. CVS Health Corporation has a 1-year low of $43.56 and a 1-year high of $72.51.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.63. The business had revenue of $94.59 billion during the quarter, compared to analyst estimates of $93.07 billion. CVS Health had a net margin of 1.39% and a return on equity of 10.59%. CVS Health's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.31 earnings per share. As a group, equities research analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current year.

Insider Activity at CVS Health

In related news, Director Guy P. Sansone purchased 1,570 shares of the stock in a transaction that occurred on Thursday, June 5th. The stock was acquired at an average price of $63.70 per share, with a total value of $100,009.00. Following the completion of the acquisition, the director now directly owns 12,007 shares in the company, valued at approximately $764,845.90. This trade represents a 15.04% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.22% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

CVS has been the topic of several analyst reports. Piper Sandler increased their target price on shares of CVS Health from $72.00 to $74.00 and gave the stock an "overweight" rating in a research report on Friday, March 21st. Morgan Stanley reissued an "overweight" rating on shares of CVS Health in a research report on Tuesday, April 15th. Mizuho lifted their target price on CVS Health from $70.00 to $76.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 9th. UBS Group lifted their target price on CVS Health from $67.00 to $71.00 and gave the stock a "neutral" rating in a research report on Friday, May 2nd. Finally, Royal Bank Of Canada lifted their target price on CVS Health from $74.00 to $81.00 and gave the stock an "outperform" rating in a research report on Monday, May 5th. Two investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, CVS Health has an average rating of "Moderate Buy" and a consensus price target of $74.75.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.